• MannKind Corporation recently reported Q1 2026 revenues of US$90.2 million, a 15% year-on-year increase driven mainly by Furoscix net sales and Tyvaso DPI royalties, alongside an expanded collaboration with United Therapeutics that includes a US$5 million payment to accelerate Ralinepag DPI development.
• With key upcoming FDA action dates for Afrezza’s pediatric indication and the Furoscix ReadyFlow Autoinjector, MannKind’s revenue mix and partnership profile are becoming more closely tied to its inhaled and drug-delivery platform capabilities.
• Now we’ll examine how the recent revenue growth and expanded United Therapeutics partnership could influence MannKind’s broader investment narrative.

The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

MannKind Investment Narrative Recap

To own MannKind, you need to believe its inhaled drug delivery platform can translate into a broader, durable revenue base beyond Afrezza and Tyvaso DPI royalties. The Q1 2026 revenue lift and new Ralinepag DPI payment support that platform story, but the near term catalyst remains the upcoming FDA decision on pediatric Afrezza, while the biggest risk is still concentration in a small set of products and partnerships.

The most relevant update here is the expanded collaboration with United Therapeutics for Ralinepag DPI, which brought in a US$5 million payment. This matters because it reinforces MannKind’s role as a partner on inhaled pulmonary therapies, directly connected to Tyvaso DPI royalties and the upcoming Furoscix ReadyFlow Autoinjector decision, both of which could influence how exposed the business remains to a narrow core portfolio.

Yet against that opportunity, investors should still pay close attention to how vulnerable MannKind remains to setbacks in a few key partnered products...

MannKind's narrative projects $544.8 million revenue and $62.0 million earnings by 2029.

Uncover how MannKind's forecasts yield a $7.17 fair value, a 121% upside to its current price.

Exploring Other Perspectives

Before this news, the most bullish analysts expected annual revenue growth of about 24.6 percent and earnings near US$120.5 million by 2029, which is far more optimistic than the baseline view and contrasts sharply with concerns about limited product diversification, reminding you that opinions can differ widely and may shift as the latest results and partnership updates are absorbed.

Explore 3 other fair value estimates on MannKind - why the stock might be worth just $4.66!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your MannKind research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free MannKind research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate MannKind's overall financial health at a glance.

Looking For Alternative Opportunities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.